Loss of muscle mass, decreased bone growth, and the risks for cognitive deficiencies become higher
Evernorth benefit program - Through direct negotiations with manufacturers, this program ensures patients' monthly costs won't exceed $200, potentially saving up to $3,600 annually compared to direct purchasing
The company raised $287 million to accelerate the development of its oral GLP-1 therapy and broader cardiometabolic pipeline
Sun Pharma is developing utreglutide, a longacting GLP1 designed to offer metabolic benefits with potentially lower cost and broader accessibility, positioning the company as a future valuedriven challenger to the highpriced injectable and oral franchises of Novo and Lilly
Missed doses create gaps in that evaluation, making it unclear whether a lack of appetite suppression reflects an inadequate dose or poor adherence
If eligible, youll receive a once-weekly GLP-1 injection as part of your personalized weight loss plan